Kathleen Scott - 21 Aug 2025 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Signature
/s/ Kathleen Scott
Issuer symbol
SPRY
Transactions as of
21 Aug 2025
Net transactions value
-$168,750
Form type
4
Filing time
22 Aug 2025, 16:30:13 UTC
Previous filing
22 May 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Scott Kathleen D. Chief Financial Officer C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO /s/ Kathleen Scott 22 Aug 2025 0001794284

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRY Common Stock Options Exercise $18,750 +12,500 +124% $1.50 22,542 21 Aug 2025 Direct F1
transaction SPRY Common Stock Sale $187,500 -12,500 -55% $15.00 10,042 21 Aug 2025 Direct F2
holding SPRY Common Stock 8,250 21 Aug 2025 By Scott 2008 Trust Dated 3/28/08

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -12,500 -1.7% $0.000000 739,830 21 Aug 2025 Common Stock 12,500 $1.50 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes 2,618 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on June 30, 2025.
F2 The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on May 22, 2025.
F3 Immediately exercisable.